{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:30Z","timestamp":1753891050687,"version":"3.41.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Passive antibody therapy has been used to treat outbreaks of viral disease, including the ongoing pandemic of severe respiratory acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) or COVID-19. However, the real benefits of the procedure are unclear. We infused a concentrated solution of neutralizing anti-SARS-CoV-2 antibodies obtained from a convalescent donor with a single session of double filtration plasmapheresis (DFPP) into a 56-year-old woman with long history of unremitting, severe COVID-19. She was unable to establish an adequate antiviral immune response because of previous chemotherapy, including the infusion of the anti-CD20 monoclonal antibody rituximab, administered to treat a diffuse large B-cell lymphoma. The disease promptly recovered despite evidence of no endogenous anti-SARS-CoV-2 antibody production. The observation that passive antibody therapy might prove particularly effective in immunodepressed COVID-19 patients requires evaluation in prospective randomized controlled trial.<\/jats:p>","DOI":"10.3389\/fimmu.2021.711915","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T06:50:42Z","timestamp":1625035842000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis"],"prefix":"10.3389","volume":"12","author":[{"given":"Diego","family":"Curt\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Tomatis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Gastoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Galbusera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Noris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando Luca","family":"Lorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-6448","article-title":"Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel","volume":"174","author":"Pau","year":"2021","journal-title":"Ann Intern Med"},{"key":"B2","unstructured":""},{"key":"B3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of Convalescent Plasma Therapy in SARS Patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc070359","article-title":"Treatment With Convalescent Plasma for Influenza A (H5N1) Infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031304","article-title":"A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia","volume":"384","author":"Simonovich","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3939","article-title":"PLACID Trial Collaborators. Convalescent Plasma in the Management of Moderate Covid-19 in Adults in India: Open Label Phase II Multicentre Randomised Controlled Trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2002.00428.x","article-title":"Double Filtration Plasmapheresis in Critical Care","volume":"6","author":"Mineshima","year":"2002","journal-title":"Ther Apher"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV Immunoglobulin Treatment: A Multicenter Double-Blind Randomized Controlled Trial for Patients With Severe 2009 Influenza A(H1N1) Infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000501858","article-title":"Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients With Severe Membranous Nephropathy: Preliminary Findings With Double Filtration Plasmapheresis and Ofatumumab","volume":"144","author":"Podest\u00e0","year":"2020","journal-title":"Nephron"},{"key":"B13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An Ex\u00a0Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B14","unstructured":"Consiglio Superiore Di Sanit\u00e0"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.02063.x","article-title":"Activity of Clotting Factors in Fresh-Frozen Plasma During Storage at 4 Degrees C Over 6 Days","volume":"49","author":"von Heymann","year":"2009","journal-title":"Transfusion"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2010.07.004","article-title":"Analysis of the Products of Cryoprecipitation: RiCoF Is Deficient in Cryosupernatant Plasma","volume":"43","author":"Freedman","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"B18","first-page":"1","article-title":"FV, FVIII and Fibrinogen Activity in Fresh Frozen Plasma, Frozen Plasma and Cryoprecipitate: Observational Cross-Sectional Study","volume":"2","author":"Youssef","year":"2019","journal-title":"Asian Hematol Res J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1800.x","article-title":"Cryosupernatant as Replacement Fluid for Plasma Exchange in Thrombotic Thrombocytopenic Purpura. Members of the Canadian Apheresis Group","volume":"94","author":"Rock","year":"1996","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.596761","article-title":"Case Report: Convalescent Plasma, a Targeted Therapy for Patients With CVID and Severe COVID-19","volume":"11","author":"Van Damme","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2003138117","article-title":"Cell Entry Mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.711915\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T06:50:45Z","timestamp":1625035845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.711915\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2021.711915"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.711915","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"article-number":"711915"}}